Impact of Adding Bevacizumab to Paclitaxel + Carboplatin for Platinum-Sensitive Recurrent Epithelial Ovarian Cancer: A Propensity Score Matching Analysis.

Abstract

PURPOSE:

We evaluated whether adding bevacizumab (Bev) to paclitaxel+carboplatin (TC) could improve outcomes, especially progression-free survival (PFS), in patients with platinum-sensitive recurrent ovarian cancer.

PATIENTS AND METHODS:

Among patients with platinum-sensitive recurrent ovarian cancer treated at our hospital from May 2008 to March 2017, PFS was compared between those receiving platinum-based chemotherapy or TC+Bev therapy by propensity score matching analysis.

RESULTS:

Nineteen patients received platinum-based chemotherapy and 13 patients received TC+Bev therapy. PFS (the primary endpoint) was 6.31 months in the platinum-based chemotherapy group versus 14.71 months in the TC+Bev group (hazard ratio: 0.304; 95% confidence interval: 0.114-0.8121; p=0.01752). The safety profile was similar to that expected.

CONCLUSION:

Adding Bev to TC prolonged PFS in patients with platinum-sensitive recurrent ovarian cancer and adverse effects were tolerable.

• Authors: Takeshi Hirasawa, Hiroko Machida, Tetsuji Iida, Masae Ikeda, Masako Shida, Mikio Mikami
• Journal: The Tokai journal of experimental and clinical medicine (Tokai J Exp Clin Med) Vol. 43 Issue 3 Pg. 85-89 (Sep 20 2018) ISSN: 2185-2243 [Electronic] Japan
• PMID: 30191541 (Publication Type: Journal Article, Observational Study)

Chemical References

• Bevacizumab
• Carboplatin
• Paclitaxel

Topics

• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Bevacizumab (administration & dosage)
• Carboplatin (administration & dosage)
• Carcinoma, Ovarian Epithelial
• Disease-Free Survival
• Drug Resistance, Neoplasm
• Female
• Humans
• Middle Aged
• Neoplasm Recurrence, Local (drug therapy)
• Neoplasms, Glandular and Epithelial (drug therapy)
• Ovarian Neoplasms (drug therapy)
• Paclitaxel (administration & dosage)
• Propensity Score
• Retrospective Studies
• Time Factors
• Treatment Outcome